Metraipolis › archive › dc_985f7b4fe4f3

Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial — Europe PMC PMID:40954146

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40954146
DOI
10.1038/s41392-[numero omesso]-9
License (as archived)
solo-consultazione
Archived
2026-11-09T22:22:38.594Z
SHA-256 of the archived text
a3aba0b619bfa5cb43ea925d925f5d0fb8ff3a00f5022534a550b19f38cb6d88
Stable URL of this page
https://metraipolis.com/documento/dc_985f7b4fe4f3

How to cite

Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial — Europe PMC PMID:40954146 — Europe PMC (en), https://europepmc.org/article/MED/40954146 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_985f7b4fe4f3 (Metraipolis archive dc_985f7b4fe4f3, sha256 a3aba0b619bfa5cb43ea925d925f5d0fb8ff3a00f5022534a550b19f38cb6d88)
BibTeX
@misc{dc985f7b4fe4f3,
  title = {Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial — Europe PMC PMID:40954146},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40954146},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_985f7b4fe4f3; sha256 a3aba0b619bfa5cb43ea925d925f5d0fb8ff3a00f5022534a550b19f38cb6d88},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40954146. Agents can read the archived copy with the MCP tool read_document.